{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BGB-11417", "query": { "intervention": "BGB-11417" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BGB-11417&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-21T12:55:10.179Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07277231", "title": "A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2026-01-22", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-21T12:55:10.179Z", "location_count": 21, "location_summary": "Duarte, California • Orange, California • Palo Alto, California + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07277231" }, { "nct_id": "NCT06854003", "title": "BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma", "Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Sonrotoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Christine Ryan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-04-22", "completion_date": "2039-11-01", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-09-21T12:55:10.179Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06854003" }, { "nct_id": "NCT06849713", "title": "Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma (SLL)" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tacabrutideg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-05-16", "completion_date": "2030-03-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-21T12:55:10.179Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06849713" }, { "nct_id": "NCT06697184", "title": "A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "CLL", "Mantle Cell Lymphoma", "MCL" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2025-01-23", "completion_date": "2032-11-30", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-21T12:55:10.179Z", "location_count": 6, "location_summary": "Tampa, Florida • Fort Wayne, Indiana • Westwood, Kansas + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06697184" }, { "nct_id": "NCT06637501", "title": "A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2024-11-14", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-21T12:55:10.179Z", "location_count": 11, "location_summary": "Weston, Florida • Marietta, Georgia • Niles, Illinois + 6 more", "locations": [ { "city": "Weston", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Niles", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06637501" }, { "nct_id": "NCT06859008", "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3a Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Nodal Marginal Zone Lymphoma", "Recurrent Splenic Marginal Zone Lymphoma", "Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Refractory Grade 1 Follicular Lymphoma", "Refractory Grade 2 Follicular Lymphoma", "Refractory Grade 3a Follicular Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2025-08-25", "completion_date": "2029-01-31", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-21T12:55:10.179Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06859008" }, { "nct_id": "NCT06543043", "title": "A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Not Determined" ], "interventions": [ { "name": "Phenytoin", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "sonrotoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2024-08-19", "completion_date": "2024-11-07", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-09-21T12:55:10.179Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06543043" }, { "nct_id": "NCT04973605", "title": "A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 246, "start_date": "2021-09-16", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-21T12:55:10.179Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Duarte, California • Irvine, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04973605" }, { "nct_id": "NCT05952037", "title": "A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom Macroglobulinemia", "Waldenstrom's Macroglobulinemia Recurrent", "Waldenstrom's Macroglobulinemia Refractory" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2023-10-23", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-09-21T12:55:10.179Z", "location_count": 17, "location_summary": "Duarte, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Warrenville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05952037" }, { "nct_id": "NCT04277637", "title": "Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mature B-Cell Malignancies" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 437, "start_date": "2020-03-24", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-09-21T12:55:10.179Z", "location_count": 13, "location_summary": "Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04277637" } ] }